» Articles » PMID: 31331365

Tenofovir-associated Renal Toxicity in a Cohort of HIV Infected Patients in Ghana

Overview
Journal BMC Res Notes
Publisher Biomed Central
Date 2019 Jul 24
PMID 31331365
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Tenofovir disoproxil fumarate (TDF) is a nucleotide analogue recommended in international HIV treatment guidelines. Purpose of this study was to estimate the long term effects of TDF on renal profile in a cohort of HIV patients in Ghana. Three hundred (300) consecutive HIV-positive patients who initiated TDF-based antiretroviral treatment in 2008 at the Korle-Bu Teaching Hospital were sampled. Creatinine clearance (CrCl) was calculated using the Cockcroft-Gault equation at baseline and renal impairment was defined as CrCl values of 30.0-49.9 mL/min (moderate renal impairment) and < 30 mL/min (severe renal impairment) as per institutional guidelines for renal function test.

Results: Median follow up time was 2.9 years (IQR 2.3-3.4 years). At study endpoint, 63 participants (21.0% [95% CI 6.5-26.1]) recorded CrCl rate below 50 mL/min indicating incident renal impairment, made up of 18.3% moderate renal impairment and 2.3% severe renal impairment. Factors associated with incidence of renal impairment were increasing age, decrease in creatinine clearance rate at baseline, WHO HIV stage III/IV and participants with BMI of < 18.5 kg/m. Patients with identified renal impairment risk factors at ART initiation should be targeted and monitored effectively to prevent renal injury.

Citing Articles

Chronic kidney disease among people living with HIV on TDF based regimen: A systematic review and meta-analysis.

Yazie T, Shiferaw W, Gebeyehu A, Teshome A, Addisu Z, Belete A PLoS One. 2025; 20(2):e0318068.

PMID: 39913460 PMC: 11801554. DOI: 10.1371/journal.pone.0318068.

References
1.
Karras D, Heilpern K, Riley L, Hughes L, Gaughan J . Urine dipstick as a screening test for serum creatinine elevation in emergency department patients with severe hypertension. Acad Emerg Med. 2002; 9(1):27-34. DOI: 10.1111/j.1553-2712.2002.tb01163.x. View

2.
Gallant J, Staszewski S, Pozniak A, DeJesus E, Suleiman J, Miller M . Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA. 2004; 292(2):191-201. DOI: 10.1001/jama.292.2.191. View

3.
Madeddu G, Bonfanti P, De Socio G, Carradori S, Grosso C, Marconi P . Tenofovir renal safety in HIV-infected patients: results from the SCOLTA Project. Biomed Pharmacother. 2007; 62(1):6-11. DOI: 10.1016/j.biopha.2007.04.008. View

4.
Goicoechea M, Liu S, Best B, Sun S, Jain S, Kemper C . Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy. J Infect Dis. 2008; 197(1):102-8. DOI: 10.1086/524061. View

5.
Horberg M, Tang B, Towner W, Silverberg M, Bersoff-Matcha S, Hurley L . Impact of tenofovir on renal function in HIV-infected, antiretroviral-naive patients. J Acquir Immune Defic Syndr. 2009; 53(1):62-9. DOI: 10.1097/QAI.0b013e3181be6be2. View